{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T08:11:30Z","timestamp":1791447090878,"version":"4.3.3"},"reference-count":20,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart, Lung, and Blood Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017540","name":"National Heart Lung and Blood Institute Division of Intramural Research","doi-asserted-by":"publisher","award":["R00HL159230"],"award-info":[{"award-number":["R00HL159230"]}],"id":[{"id":"10.13039\/100017540","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jtha.2024.10.009","type":"journal-article","created":{"date-parts":[[2024,10,21]],"date-time":"2024-10-21T15:53:41Z","timestamp":1729526021000},"page":"546-555","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7982-7419","authenticated-orcid":false,"given":"Ghadeer K.","family":"Dawwas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Cuker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.10.009_bib1","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","year":"2023","journal-title":"J\u00a0Am Geriatr Soc"},{"key":"10.1016\/j.jtha.2024.10.009_bib2","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.583311","article-title":"Effectiveness and safety of oral anticoagulants in older patients with atrial fibrillation: a systematic review and meta-analysis","volume":"11","author":"Grymonprez","year":"2020","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jtha.2024.10.009_bib3","doi-asserted-by":"crossref","first-page":"463","DOI":"10.7326\/M19-2522","article-title":"Effectiveness and safety of apixaban compared with rivaroxaban for patients with atrial fibrillation in routine practice: a cohort study","volume":"172","author":"Fralick","year":"2020","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.10.009_bib4","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1001\/jama.2021.21222","article-title":"Association of rivaroxaban vs apixaban with major ischemic or hemorrhagic events in patients with atrial fibrillation","volume":"326","author":"Ray","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.jtha.2024.10.009_bib5","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.7326\/M22-0318","article-title":"Apixaban versus rivaroxaban in patients with atrial fibrillation and valvular heart disease: a population-based study","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.10.009_bib6","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M21-0717","article-title":"Risk for recurrent venous thromboembolism and bleeding with apixaban compared with rivaroxaban: an analysis of real-world data","volume":"175","author":"Dawwas","year":"2022","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.10.009_bib7","article-title":"Drug-drug interaction of rivaroxaban and calcium channel blockers in patients aged 80 years and older with nonvalvular atrial fibrillation","volume":"35","author":"Sychev","year":"2020","journal-title":"Drug Metab Pers Ther"},{"key":"10.1016\/j.jtha.2024.10.009_bib8","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1080\/07853890.2021.2017474","article-title":"Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis","volume":"54","author":"Nochaiwong","year":"2022","journal-title":"Ann Med"},{"key":"10.1016\/j.jtha.2024.10.009_bib9","doi-asserted-by":"crossref","first-page":"E173","DOI":"10.1002\/ajh.26494","article-title":"Apixaban has superior effectiveness and safety compared to rivaroxaban in patients with commercial healthcare coverage: a population-based analysis in response to CVS 2022 formulary changes","volume":"97","author":"Dawwas","year":"2022","journal-title":"Am J Hematol"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.10.009_bib11","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/pds.2317","article-title":"A\u00a0systematic review of validated methods for identifying atrial fibrillation using administrative data","volume":"21","author":"Jensen","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtha.2024.10.009_bib12","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1161\/01.STR.0000174293.17959.a1","article-title":"Coding of stroke and stroke risk factors using international classification of diseases, revisions 9 and 10","volume":"36","author":"Kokotailo","year":"2005","journal-title":"Stroke"},{"key":"10.1016\/j.jtha.2024.10.009_bib13","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1161\/CIRCOUTCOMES.113.000371","article-title":"Validity of international classification of disease codes to identify ischemic stroke and intracranial hemorrhage among individuals with associated diagnosis of atrial fibrillation","volume":"8","author":"Thigpen","year":"2015","journal-title":"Circ Cardiovasc Qual Outcomes"},{"key":"10.1016\/j.jtha.2024.10.009_bib14","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1097\/01.mlr.0000182534.19832.83","article-title":"Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data","volume":"43","author":"Quan","year":"2005","journal-title":"Med Care"},{"key":"10.1016\/j.jtha.2024.10.009_bib15","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/pds.2109","article-title":"An automated database case definition for serious bleeding related to oral anticoagulant use","volume":"20","author":"Cunningham","year":"2011","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jtha.2024.10.009_bib16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.7326\/M16-2607","article-title":"Sensitivity analysis in observational research: introducing the E-value","volume":"167","author":"VanderWeele","year":"2017","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2024.10.009_bib17","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.55838","article-title":"Prevalence and incidence of atrial fibrillation among older primary care patients","volume":"6","author":"Khurshid","year":"2023","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.jtha.2024.10.009_bib18","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1001\/jamainternmed.2016.5954","article-title":"Stroke, bleeding, and mortality risks in elderly medicare beneficiaries treated with dabigatran or rivaroxaban for nonvalvular atrial fibrillation","volume":"176","author":"Graham","year":"2016","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.jtha.2024.10.009_bib19","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0213614","article-title":"Effectiveness and safety of oral anticoagulants in older adults with non-valvular atrial fibrillation and heart failure","volume":"14","author":"Amin","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2024.10.009_bib20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus warfarin in nonvalvular atrial fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.10.009_bib21","doi-asserted-by":"crossref","first-page":"2505","DOI":"10.1007\/s11606-020-05904-0","article-title":"Oral anticoagulant utilization in the united states and united kingdom","volume":"35","author":"Colacci","year":"2020","journal-title":"J\u00a0Gen Intern Med"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624006160?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624006160?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T16:44:32Z","timestamp":1749141872000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624006160"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":20,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1538783624006160"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.009","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative effectiveness and safety of rivaroxaban with other oral anticoagulants in older adults with nonvalvular atrial fibrillation: population-based analysis in response to updated Beers Criteria","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.10.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}